Source: Healio News
Black patients appeared consistently underrepresented in pivotal clinical trials that led to FDA approval of several chimeric antigen receptor T-cell therapies, according to findings published in JAMA Network Open.
Researchers from University of Arkansas for Medical Sciences observed a paucity of Black participants across pivotal trials regardless of the CAR-T product type or the disease being treated. A clinical trial evaluating an FDA-approved CAR-T for multiple myeloma had the most pronounced participation disparity, researchers noted.
CAR T-cell therapy for hematologic malignancies has